Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ajt.16241 http://scihub22266oqcxt.onion/10.1111/ajt.16241 32881315!7436464!32881315     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32881315&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Am+J+Transplant 2020 ; 20 (11): 3072-3080 Nephropedia Template TP {{tp|p=32881315|t=2020. COVID-19 in lung transplant recipients: A single center case series from New York City |pdf=|usr=}}{{32881315}} gab.com Text COVID-19 in lung transplant recipients: A single center case series from New York City JO: Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32881315 #FOAvip There are limited data describing COVID-19 in lung transplant recipients. We performed a single center, retrospective case series study of lung transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS-CoV-2 between March 19 and May 19, 2020. Thirty-two lung transplant patients developed mild (16%), moderate (44%), or severe (41%) COVID-19. The median age of patients was 65 years, and the median time from lung transplant was 5.6 years. Symptoms included cough (66%), dyspnea (50%), fever (47%), and gastrointestinal upset (44%). Patients received hydroxychloroquine (84%), azithromycin (75%), augmented steroids (44%), tocilizumab (19%), and remdesivir (9%). Eleven patients (34%) died at a median time of 14 days from admission. Complications during admission included: acute kidney injury (63%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events (25%), arrhythmias (22%), and venous thromboembolism (9%). Compared to patients with moderate COVID-19, patients with severe COVID-19 had higher peak white blood cell counts (15.8 vs 7 x 10(3) /uL, P = .019), C-reactive protein (198 vs. 107 mg/L, P = .010) and D-dimer (8.6 vs. 2.1 ug/mL, P = .004) levels, and lower nadir lymphocyte counts (0.09 vs. 0.4 x 10(3) /uL, P = .006). COVID-19 is associated with severe illness and a high mortality rate in lung transplant recipients. Twit Text FOAVip COVID-19 in lung transplant recipients: A single center case series from New York City ????Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32881315 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32881315 #FOAvip English Wikipedia <ref>{{Cite pmid|32881315}}</ref> COVID-19 in lung transplant recipients: A single center case series from New York City #MMPMID32881315 Aversa M; Benvenuto L; Anderson M; Shah L; Robbins H; Pereira M; Scheffert J; Carroll M; Hum J; Nolan M; Reilly G; Lemaitre P; Stanifer BP; D'Ovidio F; Sonett J; Arcasoy S Am J Transplant 2020[Nov]; 20 (11): 3072-3080 PMID32881315show ga There are limited data describing COVID-19 in lung transplant recipients. We performed a single center, retrospective case series study of lung transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS-CoV-2 between March 19 and May 19, 2020. Thirty-two lung transplant patients developed mild (16%), moderate (44%), or severe (41%) COVID-19. The median age of patients was 65 years, and the median time from lung transplant was 5.6 years. Symptoms included cough (66%), dyspnea (50%), fever (47%), and gastrointestinal upset (44%). Patients received hydroxychloroquine (84%), azithromycin (75%), augmented steroids (44%), tocilizumab (19%), and remdesivir (9%). Eleven patients (34%) died at a median time of 14 days from admission. Complications during admission included: acute kidney injury (63%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events (25%), arrhythmias (22%), and venous thromboembolism (9%). Compared to patients with moderate COVID-19, patients with severe COVID-19 had higher peak white blood cell counts (15.8 vs 7 x 10(3) /uL, P = .019), C-reactive protein (198 vs. 107 mg/L, P = .010) and D-dimer (8.6 vs. 2.1 ug/mL, P = .004) levels, and lower nadir lymphocyte counts (0.09 vs. 0.4 x 10(3) /uL, P = .006). COVID-19 is associated with severe illness and a high mortality rate in lung transplant recipients. |*Lung Transplantation[MESH] |*Pandemics[MESH] |*SARS-CoV-2[MESH] |*Transplant Recipients[MESH] |Adult[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*epidemiology[MESH] |Female[MESH] |Graft Rejection/epidemiology/*prevention & control[MESH] |Humans[MESH] |Immunosuppression Therapy/methods[MESH] |Incidence[MESH] |Male[MESH] |Middle Aged[MESH] |New York City/epidemiology[MESH] |Retrospective Studies[MESH]COVID-19 in lung transplant recipients: A single center case series fr(epmc).pdf DeepDyve Pubget Overpricing